MedTrace Logo

Non-comparative Trial of the Combination of HCQ and AZI in the Treatment of ICU Patients

NCT04458948 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2023-09-13

Study results available
· View outcomes & findings →

Summary

This research is designed as an open-label,non-comparative prospective trial.

Conditions

Interventions

DRUG

Hydroxychloroquine

Hydroxychloroquine 400 mg BID, on day 1 and then 200 mg BID day 2 through 7 IV or po for 5 days. If the condition of the patient does not allow for oral therapy, HCQ can be given via a feeding or NG tube. Azithromycin can be given intravenously.

DRUG

Azithromycin

Azithromycin 500 mg, IV or po for 5 days

Sponsors & Collaborators

  • University of New Mexico

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-24
Primary Completion
2020-08-28
Completion
2020-08-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04458948 on ClinicalTrials.gov